Cypralis has entered into a collaboration with Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases. The terms were not disclosed.
Cyclophilin inhibitors on the market or in development are non-selective between the four commonly screened cyclophilin isoforms A, B, C and D. Cypralis and Janssen are undertaking a joint research program to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D applicable to targeting degenerative diseases including CNS degeneration. The medicinal chemistry and PPIase screening will be sub-contracted to Selcia Limited.
Simon Kerr, CEO of Cypralis commented: “We are delighted to be collaborating with Janssen in order to develop a novel class of cyclophilin D inhibitors. We are hopeful that this effort will pave the way towards a new approach to the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
